Jing Xu at LYFE Capital has an unusually complete healthcare background spanning PhD pharmaceutical sciences, big pharma commercial launches, corporate development, and venture investing before returning to operations as VP of Global Strategy at Sciwind while maintaining her LYFE association—creating a rare research-to-commercial-to-investor-to-operator loop within the same sector. Her investment track record includes leading deals with companies like MediLink (partnered with Roche and BioNTech), ProfoundBio (acquired by Genmab), and Sciwind, demonstrating a pattern of backing Asian biotechs that become credible global partners rather than staying purely domestic.